These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36123181)

  • 21. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
    Holland EA; Schmid H; Kefford RF; Mann GJ
    Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma.
    Ghiorzo P; Gargiulo S; Pastorino L; Nasti S; Cusano R; Bruno W; Gliori S; Sertoli MR; Burroni A; Savarino V; Gensini F; Sestini R; Queirolo P; Goldstein AM; Scarrà GB
    Hum Mol Genet; 2006 Sep; 15(18):2682-9. PubMed ID: 16893909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors.
    Piepkorn M
    J Am Acad Dermatol; 2000 May; 42(5 Pt 1):705-22; quiz 723-6. PubMed ID: 10775844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
    Nielsen GP; Burns KL; Rosenberg AE; Louis DN
    Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
    Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
    Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention.
    Fan M; Pfeffer SR; Lynch HT; Cassidy P; Leachman S; Pfeffer LM; Kopelovich L
    Oncotarget; 2013 Jan; 4(1):128-41. PubMed ID: 23371019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel germline CDKN2A mutation associated with head and neck squamous cell carcinomas and melanomas.
    Cabanillas R; Astudillo A; Valle M; de la Rosa J; Álvarez R; Durán NS; Cadiñanos J
    Head Neck; 2013 Mar; 35(3):E80-4. PubMed ID: 22083977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
    Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
    J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
    Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
    Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
    Horn IP; Marks DL; Koenig AN; Hogenson TL; Almada LL; Goldstein LE; Romecin Duran PA; Vera R; Vrabel AM; Cui G; Rabe KG; Bamlet WR; Mer G; Sicotte H; Zhang C; Li H; Petersen GM; Fernandez-Zapico ME
    J Biol Chem; 2021; 296():100634. PubMed ID: 33823155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
    Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP
    Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
    Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
    Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
    Sheppard KE; McArthur GA
    Clin Cancer Res; 2013 Oct; 19(19):5320-8. PubMed ID: 24089445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional reassessment of P16 variants using a transfection-based assay.
    Walker GJ; Gabrielli BG; Castellano M; Hayward NK
    Int J Cancer; 1999 Jul; 82(2):305-12. PubMed ID: 10389768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF.
    Pasmant E; Laurendeau I; Héron D; Vidaud M; Vidaud D; Bièche I
    Cancer Res; 2007 Apr; 67(8):3963-9. PubMed ID: 17440112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
    Ceha HM; Nasser I; Medema RH; Slebos RJ
    Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma.
    Mohseny AB; Tieken C; van der Velden PA; Szuhai K; de Andrea C; Hogendoorn PC; Cleton-Jansen AM
    Genes Chromosomes Cancer; 2010 Dec; 49(12):1095-103. PubMed ID: 20737480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [CDKN2A gene in melanoma].
    Liu MT; Liu JY; Su J
    Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):909-912. PubMed ID: 31775447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age does not appear to be a major indicator of CDKN2A or CDK4 mutations in melanoma patients in Spain.
    Nagore E; Montoro A; Oltra S; Ledesma E; Botella-Estrada R; Millán JM; Oliver V; Fortea JM; Guillén C
    Melanoma Res; 2005 Dec; 15(6):555-8. PubMed ID: 16314743
    [No Abstract]   [Full Text] [Related]  

  • 40. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
    Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
    Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.